Answers are grounded in this paper and cite their sources.
This pilot study demonstrates myo-inositol oxygenase as a prognostic biomarker for CKD progression after acute kidney injury, indicating potential clinical use.
Acute kidney injury (AKI) substantially increases the risk of chronic kidney disease (CKD) and mortality. Evidence from developing countries, particularly for community-acquired AKI (CA-AKI) is limited. Previously in a pilot study we have shown that levels of serum Myo-Inositol Oxygenase (MIOX) at the time of hospital discharge can be used as a prognostic biomarker for CKD progression after CA-AKI.
No takes yet. Share an insight, caveat, or question.
Dhiman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: